Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

Acta Oncologica

Volumn 49, Issue 3, 2010, Pages 305-312

  Lash, Timothy L ^a,b,c   Cronin Fenton, Deirdre ^a   Ahern, Thomas P ^b   Rosenberg, Carol L ^c   Lunetta, Kathryn L ^b   Silliman, Rebecca A ^c   Hamilton Dutoit, Stephen ^d   Garne, Jens Peter ^e,f   Ewertz, Marianne ^f,g   Sørensen, Henrik Toft ^a,b,f   Pedersen, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AARHUS UNIVERSITY   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f Danish Breast Cancer Cooperative Group (DBCG)   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALAPROCLATE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITUSSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CYTOCHROME P450 2D6; ESCITALOPRAM; ESTROGEN RECEPTOR; ETOPERIDONE; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; STEROID; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; DENMARK; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; RECURRENT CANCER; RECURRENT DISEASE; TREATMENT INDICATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CITALOPRAM; CYTOCHROME P-450 CYP2D6; DENMARK; DEPRESSION; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TAMOXIFEN;

EID: 77950893913     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903575273     Document Type: Article

References (29)

1. Hegel MT, Moore CP, Collins ED, Kearing S, Gillock KL, Riggs RL, et al. Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer. Cancer 2006;107:2924-2931 (Pubitemid 44937048)
2. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 2008;30:112-126 (Pubitemid 351248974)
3. Coyne JC, Palmer SC, Shapiro PJ, Thompson R, DeMichele A. Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample. General Hospital Psychiatry 2004;26:121-128 (Pubitemid 38369118)
4. Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL, Cohen LS. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 2003;64:473-479 (Pubitemid 36547294)
5. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583
6. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
7. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997;53:171-178
8. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717 (Pubitemid 40719106)
9. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55:471-478 (Pubitemid 40568978)
10. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 1988;48: 2304-2308
11. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78 (Pubitemid 26300937)
12. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165: 1251-1255
13. Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008; 99:616-621
14. Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group-DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008;47:497-505.
15. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 2008;100:218-221
16. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506-524 (Pubitemid 351878431)
17. WHO Collaborating Centre for Drug Statistics Methodology. About the Centre. http://www whocc no/atcddd/ 2008Available from: URL: http://www.whocc.no/atcddd/ 7january2010.
18. Von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-1109
19. Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007;27: 28-34. (Pubitemid 46105760)
20. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications. Cancer Epidemiol Biomarkers Prev 2009.
21. NCCN Practice Guidelines in Oncology, Breast Cancer -v.1.2010. Invasive breast cancer, adjuvant endocrine therapy. National Comprehensive Cancer Network in 2010.
22. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39
23. Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Treat Endocrinol 2006;5:83-87
24. Bijl MJ, Visser LE, Hofman A, Vulto AG, van GT, Stricker BH, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008;65:558-564 (Pubitemid 351365130)
25. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 2008;3:e1872.
26. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-833
27. Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2004; 96:883-885 (Pubitemid 38807611)
28. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-1467 (Pubitemid 28482010)
29. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-790 (Pubitemid 36798424)